Andrews University

Digital Commons @ Andrews University
Honors Theses

Undergraduate Research

11-19-2015

Anticancer Activity of Some Boronic Acid Arylidene Heterocycles
Joy Kim
Andrews University, joyk@andrews.edu

Follow this and additional works at: https://digitalcommons.andrews.edu/honors
Part of the Biology Commons, and the Medicinal Chemistry and Pharmaceutics Commons

Recommended Citation
Kim, Joy, "Anticancer Activity of Some Boronic Acid Arylidene Heterocycles" (2015). Honors Theses. 126.
https://digitalcommons.andrews.edu/honors/126

This Honors Thesis is brought to you for free and open access by the Undergraduate Research at Digital Commons
@ Andrews University. It has been accepted for inclusion in Honors Theses by an authorized administrator of
Digital Commons @ Andrews University. For more information, please contact repository@andrews.edu.

Thank you for your interest in the

Andrews University Digital Library
of Dissertations and Theses.

Please honor the copyright of this document by
not duplicating or distributing additional copies
in any form without the author’s express written
permission. Thanks for your cooperation.

2

ABSTRACT
This research was done in order to investigate the anticancer activity of boronic acid
arylidene heterocycles. Boronic acid, heterocycles, and aryl compounds have all independently
exhibited various anti-microbial properties and have shown potential to be used in

pharmaceuticals for the treatment of viruses and cancers. Using a one-step protocol developed by
Dr. Murray, several different arylheterocyclic compounds were combined with an arylboronic
acid to synthesize novel compounds. These were then tested for their anti-cancer activity on
glioblastoma brain cancer cells. Although varied in potency, all had some amount of anti-cellular
effect on the cancer cells. This is only the start of analyzing these compounds and further
research should be done in order to realize their full potential.

INTRODUCTION
The purpose of this research project is to investigate the anticancer activity of
boronic acid arylidene heterocycles. While similar studies have been conducted with these types
of compounds, the specific compounds in this study have not previously been synthesized and
tested. Dr. Murray has developed a simple one-step protocol for their chemical synthesis that
facilitates the exploring of their biological activity.
Choosing the compounds for this research was based in part on the independent
bioactivity of boronic acid and heterocycles. In recent years, the field of pharmacology has
shown a growing interest in these compounds for medicinal purposes. Boronic acid has
demonstrated anticancer [1], antibacterial [2], and antiviral [3] properties in past research, and
one of the reasons behind the growing interest in boronic acid for therapeutic applications is that
boron has been found in natural products of certain bacteria and is also involved in plant
wellbeing, such as the building of cell walls [4]. The heterocyclic compounds chosen for the
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anti-microbial properties of their family compounds were rhodanine [5,6], 2,4-thiazolidinedione
[6,7], hydantoin and pseudothyiohydantoin [8,9], and 3-methyl-1-phenyl-2-pyrazoline-5-one
[10].
While some of the previous research has put effort into investigating the mechanisms by
which the compounds work, the purpose of this study is simply to look for the presence, if any,
of anti-cancer properties of these novel compounds. The testing of these compounds were done
on brain cancer cells. To date, brain cancer has been difficult to diagnose patients early on, and

risk factors are not well understood. This combined with the complications of treating the disease
due to the blood-brain barrier leads to a poor prognosis [11]. Thus, brain cancer cells were
chosen as a good option for potentially expanding the body of knowledge concerning its
treatment.

METHODS
Synthesizing Compounds:
Five different compounds were combined with the ortho, para, and meta substituted
isomers of formylphenylboronic acid (thus three different reactions were performed for each
compound). The compounds were rhodanine, 2,4-thiazolidinedione, pseudothiohydantoin,
hydantoin, and 3-methyl-1-phenyl-2-pyrazoline-5-one. Ethanol was used as a biodegradable
solvent, and calcium oxide was used as a nontoxic catalyst. The general protocol for the
synthesis of all of the compounds was a nontoxic one-step procedure and is as follows. In a 25
mL round bottom flask, 20 mL of ethanol, 5 mmol of formylpheylboronic acid, 5 mmol of the
variable compound, and 15 mmol of calcium oxide were added in that order. A stir bar was also
added to the flask, which was then placed on a magnetic hot plate. A water-cooled condenser

was attached to the flask, and the mixture was heated under reflux for 4 hours. Afterwards the
mixture was poured into an ice bath with 30 mL of saturated ammonium chloride as a
neutralizing agent. After stirring for at least 10 minutes, vacuum filtration was performed in
order to isolate the solid product. No further purification was performed.
The compounds were analyzed with NMR to determine if the reaction had successfully
made the desired product. If the NMR indicated that traces of the reactants were still in the
product, the compound was not used in testing with the cancer cells.

Cell line and cell culture:
The cells tested are glioblastoma brain cancer cells (U87MG cell line) and were ordered
from American Type Culture Collection (ATCC). Minimal Essential Media (MEM) was
obtained from Invitrogen and contained 10% fetal bovine serum and 1% penicillin and
streptomycin. The media was changed 3 times per week and the cell plates were kept in an
incubator at 37˚C and 5% carbon dioxide level.

Testing compounds:
The LD50 could not be obtained because of visibility limitations. The reason for this is
that since a hemocytometer was used to count the cells, once the compound concentration
exceeded 0.25M, it became too cloudy to accurately count the cells. Thus, in order to test the
potency of the compounds, several fixed concentrations of the compounds were administered to
the glioblastoma cancer cells. The cells were grown on plates with MEM, and then allocated
onto new plates for the trials with roughly 500,000 cells on each plate. This was done by
suspending the cells with trypsin, determining cell density with a hemocytometer, and then
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distributing the appropriate amount of trypsin onto new plates accordingly. After setting up the
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plates and giving sufficient time for the cells to attach onto the plate (minimum 6 hours but was
usually around 24 hours). The compounds were dissolved in DMSO and added to the plates in
concentrations of 0.05M, 0.1M and 0.25M, with 1ml of DMSO and compound for every 3ml of
MEM. DMSO was used because ethanol would have been the only other solvent that could have
dissolved the compounds but would have killed the cells. Also, the properties of DMSO allow it
to enter the cells, along with any substances it has dissolved. For each trial run, one plate with
only cells and the media, as well as one plate with only pure DMSO added was also set up as
controls. After the cells had been exposed to the compound for 24 hours they were again
detached from the plate with trypsin and counted with a hemocytometer. 50µl of trypsin
containing the cells in 50µl of trypan blue dye, in order to differentiate between the cells that
were dead and alive, was counted using the hemocytometer. Three trials were performed for each
compound. The data has been expressed in % death of the cells, and T-tests (one-tailed, unequal
variance) were performed between the different compounds and the DMSO control results to
determine if there was a significant difference in cell death.

RESULTS
Out of the fifteen reactions performed, fourteen made a solid product. When analyzed
with NMR, six were found to have successfully undergone the reaction completely. This
included all three rhodanine reactions, two of the 2,4-thiazolidinedione reactions, and one
reaction with pseudothiohydantoin. The structures of the products are shown in Figure 1.
Table 1 shows the numerical results of the trials and data analysis, while Figure 2 gives a
visual representation of the data (the compounds were arbitrarily named to keep them ordered).

Table 1 also includes the results of the t-tests and, based on the p-value given, if the amount of
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cell death increased significantly when adding that compound at that concentration. It was found
that based on the t-tests, all of the compounds were associated with an increase in cell death at
some dosage. However, several of the compounds were not consistent in the sense that they had
a significant p-value for one concentration but not at a higher concentration. Notably, compound
4-R3 showed a significant increase in cell death for all three concentrations.

DISCUSSION
Looking at the data, it is somewhat difficult to interpret the results. This is due to several
reasons. First, although all of the compounds have at least one concentration at which a
significant increase in cell death occurred, a greater concentration did not always correlate with
greater amounts of cell death. Furthermore, as aforementioned, some of the compounds were
inconsistent in their significance in that sometimes at one concentration a significant p-value
would be obtained, but such would not be the case at a higher concentration for the same
compound. It appears that one of the reasons for this is that sometimes at those higher
concentrations, even if the cell death increased, standard deviation was large enough to result in
an insignificant p-value. If this high standard deviation is due to random error, further research
with more trials per compound and concentration should decrease the standard deviation and
result in more consistent data.
Another factor that affected the data collected was that adding DMSO to the cells seemed
to make them more tightly adhered to the cell plate and more resistant to trypsin. Under normal
conditions with only the cells and MEM, the cells detach fairly easily from the plate after adding
trypsin and mixing with a pipette. However, whenever the plates contained DMSO, it became

7

much more difficult to get the cells to detach, to the point where a substantial amount of the cells
that were alive were still attached to the plate and thus did not contribute to the number of alive
cells when counting with a hemocytometer. As a result, even though the relative potency would

not be affected because the control plate contained DMSO, the absolute percentages of cell death
would be positively skewed. To fix this issue, gridded plates should be used in future trials so
that cells can be counted even if they are still attached to the plate.
However, even though the effect that DMSO had on the cell attachment to the plate
caused potential issues in accurate data collection, it may also be an indicator of the therapeutic
effects of DMSO on cancer cells. The particular cancer cell line we used has an anchorageindependent trait [12], but the fact that the cells become more strongly attached to the plate
means that they are most likely losing that characteristic. This would suggest that DMSO can
somehow influence cancer cells to behave more like normal healthy cells, and further research
should be done to investigate this more thoroughly.
Although the results of this study did not provide any decisive evidence on whether or
not these compounds have anti-cancer properties, there is some indication that these compounds
as well as DMSO in itself has some potential applications for cancer treatment. Furthermore
insight was gained what should be further studied and how to improve the methodology in order
to facilitate future research. As this was the first time these compounds were tested on cells, it is
only the start of evaluating their cancer-fighting properties and medicinal applications. Thus, the
next step of research will be to test the compounds on normal cells as well to verify that the
effect the compounds have had on the cancer cells are anti-cancer properties and not merely
cytotoxic. This is important to determine because if it is the latter, they will not have as much

value and potential in the pharmaceutical realm for cancer treatment. After that, the mechanism
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by which they carry out their anti-cancer activity should be studied.

1a.

1b.

1c.

Figure 1. a) The structure of 2-R1, 3-R1, and 4-R1 (boronic acid combined with rhodanine). b)
The structure of 2-R2 and 3-R2 (boronic acid combined with 2,4-thiazolidinedione).
c) The structure of 4-R2 (boronic acid combined with pseudothiohydantoin).
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Figure 2. A chart showing the average percentage of cell death from different compounds at different
concentrations. Error bars are shown of one positive and negative standard deviation. Compound 4-R3 at 0.25M had
the highest value. Compound 3-R1 at 0.25M followed close behind, but did not have a significant p-value from the
t-test performed because of the high standard deviation.
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Compound &
Concentration
DMSO
2-R1; 0.05M
2-R1; 0.1M
2-R1; 0.25M
3-R1; 0.05M
3-R1; 0.1M
3-R1; 0.25M
4-R1; 0.05M
4-R1; 0.1M
4-R1; 0.25M
2-R2; 0.05M
2-R2; 0.1M
2-R2; 0.25M
3-R2; 0.05M
3-R2; 0.1M
3-R2; 0.25M
4-R3; 0.05M
4-R3; 0.1M
4-R3; 0.25M

Average %
Cell Death
Std Deviation
37.57
13.7257301
44.6
4.76235236
49.63333333
3.775358703
60.33333333
3.113411848
50.96666667
7.294746968
56.43333333
22.22978482
72.33333333
24.14711853
46.66666667
5.773502692
51.83333333
7.421814693
51.13333333
9.650043178
41.4
4.757099957
60.76666667
5.589573627
49.56666667
5.831237719
54.23333333
16.75599395
60.76666667
13.86590543
61.06666667
18.47953823
61.83333333
15.80263691
66.5
13.28645927
77.43333333
7.941242556

p-value
N/A
0.100246547
0.015212137
0.000263529
0.031720453
0.137841199
0.059509215
0.065673074
0.026911422
0.057800449
0.236312287
0.000977389
0.028767417
0.109220749
0.038456074
0.072055038
0.048251885
0.019253185
0.000344942

Significant?
(<0.05)
N/A
no
yes
yes
yes
no
no
no
yes
no
no
yes
yes
no
yes
no
yes
yes
yes

Table 1. Numerical values of data collected and results of t-tests. As shown, all compounds
showed a significant increase in cell death based on the t-tests, but were inconsistent in terms of
increasing concentration and staying significant. Compound 4-R3 was the only one to show a
significance for all three concentrations.

10

References
1. Harald M. H. G. Albers,‡,§ Loes J. D. Hendrickx,‡,† Rob J. P. van Tol,‡ Jens Hausmann,r
Anastassis Perrakis,r and Huib Ovaa. Structure-Based Design of Novel Boronic AcidBased Inhibitors of Autotaxin. Journal of Medicinal Chemistry. Med. Chem. 2011, 54,
4619–4626
2. Eidam, O., Romagnoli, C., Caselli, E., Babaoglu, K., Pohlhaus, D., Karpiak, J., . . . Prati, F.
(2010). Design, Synthesis, Crystal Structures, and Antimicrobial Activity of Sulfonamide
Boronic Acids as β-Lactamase Inhibitors. J. Med. Chem. Journal of Medicinal
Chemistry;53(21): 7852-7863.
3. Trippier, P., Mcguigan, C., & Balzarini, J. (2010). Phenylboronic-acid-based carbohydrate
binders as antiviral therapeutics: Monophenylboronic acids. Antiviral Chemistry &
Chemotherapy Antivir Chem Chemther, 20, 249-257. Retrieved November 10,2015 from
PubMed.
4.Trippier, P.C., and McGuigan, C. (2010). Boronic acids in medicinal chemistry: anticancer,
antibacterial and antiviral applications. MedChemComm, 1(3), 183-198. Retrieved March
18, 2015, from RSC Publishing.
5. Srinivas, M., & Rajendra Prasad, Y. (2013). Microwave Mediated Synthesis and Anticancer
Activity of some 5-Arylidinerhodanines. International Journal of Pharma Sciences, 3(1),
152-155. Retrieved March 19, 2015 from Aizeon Publishers.
6. Bhatti, R., Shah, S., Krishan, P., & Sandhu, J. (2013). Recent Pharmacological Developments
on Rhodanines and 2,4-Thiazolidinediones. International Journal of Medicinal
Chemistry, 2013, np. Retrieved March 19, 2015 from Hindawi.
7. Kaminskyy D, Bednarczyk-Cwynar B, Vasylenko O, Kazakova O, Zimenkovsky B, Zaprutko
L, Lesyk R. (2011). Synthesis of new potential anticancer agents based on 4thiazolidinone and oleanane scaffolds. Medicinal Chemistry Research, 9893-9899.
8. Tan, L., Maji, S., Mattheis, C., Zheng, M., Chen, Y., Caballero-Díaz, E., . . . Agarwal, S.
(2012). Antimicrobial Hydantoin-Containing Polyesters. Macromolecular Bioscience,
12(8), 1068-1076. Retrieved November 10, 2015 from Wiley Online Library.
9. Azam, F., Prasad, M., & Thangavel, N. (2011). Structure-based design, synthesis, and
molecular modeling studies of 1-(benzo[d]thiazol-2-yl)-3-(substituted aryl)urea
derivatives as novel anti-Parkinsonian agents. Medicinal Chemistry Research, 316(9),
2630-2643. Retrieved November 16, 2015 from PubMed.

10. Mostafa, M., El-Salam, N., & Alothman, O. (2013). Synthesis and Microbial Activity of
Novel 3-Methyl-2-pyrazolin-5-one Derivatives. Journal of Chemistry, 2013, 1-7.
Retrieved November 16, 2015 from Hindawi.

11

11. Jovčevska, I., Kočevar, N., & Komel, R. (2013). Glioma and glioblastoma ‑ how much do
we (not) know? (Review). Molecular and Clinical Oncology, 1(6), 935-941. Retrieved
November 16, 2015 from PubMed.
12. Nakahata, A., Suzuki, D., Rodini, C., Fiuza, M., & Okamoto, O. (2014). RNAi‑ mediated
knockdown of E2F2 inhibits tumorigenicity of human glioblastoma cells. Oncology
Letters, 8(4), 1487-1491. Retrieved November 10, 2015 from PubMed.

